Cellectar Biosciences (NASDAQ: CLRB) completed a securities purchase agreement that will bring in up to $140 million in new capital, consisting of $35 million in upfront cash and $105 million in milestone‑based securities, including pre‑funded and tranche warrants. The transaction is led by Nantahala Capital Management, with participation from several dedicated healthcare funds and the company’s management team, and adds Andrew Gu of Nantahala to Cellectar’s board of directors.
The capital raise is earmarked to launch the company’s confirmatory Phase 3 study of iopofosine I‑131 in relapsed or refractory Waldenström macroglobulinemia and to support the U.S. accelerated‑approval filing. The funding also underpins the company’s pursuit of a conditional marketing authorization in Europe, following the EMA’s conditional pathway approval. The milestone‑based securities will be triggered by predefined clinical and regulatory milestones, providing a structured path for future capital infusions as the program progresses.
Cellectar’s financing round was oversubscribed, underscoring strong investor confidence in its radiopharmaceutical platform and the clinical data for iopofosine I‑131. The company has been burning cash at a rapid pace, so the infusion of $140 million is critical to maintain its clinical and regulatory momentum. The Breakthrough Therapy designation from the FDA and the EMA PRIME designation further validate the therapeutic potential of iopofosine I‑131, positioning the company to address an unmet need in a rare, incurable disease.
Management emphasized that the new capital confirms the company’s strategy to pursue accelerated approval in the U.S. and conditional approval in Europe. The board addition of Andrew Gu signals continued confidence from a leading healthcare investor, reinforcing the company’s commitment to advancing its lead candidate through the clinical development pipeline.
Investors reacted positively to the announcement, noting the oversubscription and the strategic importance of the funding for the Phase 3 trial and regulatory filings. The market view reflects confidence that the capital raise will enable Cellectar to meet its clinical milestones and potentially secure regulatory approvals, which could unlock significant commercial opportunities for its radiopharmaceutical platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.